Immuron (IMRN) is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS will join Immuron’s product portfolio which includes the rapidly growing Travelan brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend. Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Immuron. “The Calmino team is happy to work with a well-established, experienced, and professional company like Immuron. We see Australia and New Zealand as important Asian Pacific markets with significant potential.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue